Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 10, 2011
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-33038
|
|
84-1475672
|
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
1180 Avenue of the Americas
19th Floor
New York, NY
|
|
10036
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(646) 214-0700
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
On June 10, 2011, ZIOPHARM Oncology, Inc. (the “Company”) issued a press release announcing that the U.S. Food & Drug Administration has accepted the Company’s investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL (INXN 2001/1001), in oncology.
A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
| |
99.1
|
Press release dated June 10, 2011
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
| |
ZIOPHARM Oncology, Inc.
|
|
| |
|
|
| |
|
|
|
|
|
By:
|
/s/ Richard Bagley |
|
| |
|
Name: Richard Bagley
|
| |
|
Title: President, Chief Operating Officer and Chief Financial Officer
|
| |
|
|
|
INDEX OF EXHIBITS
|
Exhibit No.
|
|
Description
|
| |
|
|
|
99.1
|
|
Press release dated June 10, 2011
|